Skip to content

Benefit of carica papaya leaf extract in cancer patients

A Multi-centric, Double blind, Placebo controlled, Randomized, observational study to evaluate the Efficacy, Safety and tolerability of carica papaya leaf Hydro alcoholic extraction with enriched alkaloids (290 mg) to inhibit Thrombocytopenia induced by Chemotherapy in cancer patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/008954
Enrollment
80
Registered
2017-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Cancer

Interventions

Intervention1: Carica papaya leaf Hydro alcoholic extraction with enriched alkaloids: Dose: 290mg Dosage form : Tablets Frequency: Twice daily Duration: 21 days Control Intervention1: Placebo: Do

Sponsors

Katra Phytochem Pvt ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-75 years 2. Has, Grade I to Grade III thrombocytopenia as per CTCAE criteria version 4.0 Platelet count 3. Patients undergoing chemotherapy 4. Patients with non-hematological malignancies 5. Willing and able to sign written informed consent

Exclusion criteria

Exclusion criteria: 1. Present, or history of, acute pro-myelocytic leukemia (APML), immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic-uremic syndrome (HUS) 2. Recent history of major surgery (within 2 weeks of study entry) 3. Currently taking, or participating in a study involving, platelet substitutes, platelet growth factors, or pharmacologic agents intended to enhance or decrease platelet hemostatic function 4. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study 5. Current HIV infection or hepatitis B virus or hepatitis C virus infections 6. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 7. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period 8. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test 8.Patients who are deemed unsuitable for the study by the investigator 9. Patients with palpable splenomegaly greter than or equal to 16cm below coastal margin 10. Female subjects who are pregnant or breastfeeding. Women of childbearing potential are required to have a BHCG serum or urine pregnancy test performed within 7 days prior to first study drug dose. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.

Design outcomes

Primary

MeasureTime frame
To compare the effect of Papaya Leaf Extract relative to the placebo on the platelet countsTimepoint: 21 days Twice daily

Secondary

MeasureTime frame
Percentage increase in WBC,RBC and Neutrophil count Number of chemotherapy dose reductionTimepoint: 21 days Twice daily

Countries

India

Contacts

Public ContactDr Balakrishna

Katra Phytochem Pvt ltd

nagabhushandr@katraphyto.com08023086461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026